Fig. 9.
Change in reactive oxygen species (ROS)/reactive nitrogen species (RNS) levels of lumbar dorsal root ganglion by chronic oxaliplatin administration with or without concomitant SS-31 administration. [VEH + VEH]: mice that received repeated injection of distilled water with continuous administration of saline, [VEH + OHP]: mice that received chronic oxaliplatin administration (three weekly administrations of 15 mg/kg doses) with continuous administration of saline, [SS-31 + OHP]: mice that received chronic oxaliplatin administration (three weekly administrations of 15 mg/kg doses) with continuous administration of SS-31 (5 mg kg−1 day−1). Analysis was performed 4 days after the last injection of oxaliplatin or vehicle. Data were normalized to one dorsal root ganglion level and were expressed as percentage of the mean value of the control group (n = 3 for each group). Data were given as scatter plots of the ROS/RNS levels with mean ± SEM and analyzed by one-way ANOVA (P = 0.021) followed by Bonferroni comparison tests. OHP = oxaliplatin; VEH = vehicle.

Change in reactive oxygen species (ROS)/reactive nitrogen species (RNS) levels of lumbar dorsal root ganglion by chronic oxaliplatin administration with or without concomitant SS-31 administration. [VEH + VEH]: mice that received repeated injection of distilled water with continuous administration of saline, [VEH + OHP]: mice that received chronic oxaliplatin administration (three weekly administrations of 15 mg/kg doses) with continuous administration of saline, [SS-31 + OHP]: mice that received chronic oxaliplatin administration (three weekly administrations of 15 mg/kg doses) with continuous administration of SS-31 (5 mg kg−1 day−1). Analysis was performed 4 days after the last injection of oxaliplatin or vehicle. Data were normalized to one dorsal root ganglion level and were expressed as percentage of the mean value of the control group (n = 3 for each group). Data were given as scatter plots of the ROS/RNS levels with mean ± SEM and analyzed by one-way ANOVA (P = 0.021) followed by Bonferroni comparison tests. OHP = oxaliplatin; VEH = vehicle.

Close Modal

or Create an Account

Close Modal
Close Modal